We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TRLS Trellus Health Plc

0.00 (0.00%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Trellus Health Plc LSE:TRLS London Ordinary Share GB00BNNFM402 ORD GBP0.0006
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.65 1.50 1.80 1.65 1.65 1.65 1,247,954 07:37:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Offices Of Medical Doctors 19k -6.34M -0.0392 -0.42 2.66M
Trellus Health Plc is listed in the Offices Of Medical Doctors sector of the London Stock Exchange with ticker TRLS. The last closing price for Trellus Health was 1.65p. Over the last year, Trellus Health shares have traded in a share price range of 1.65p to 9.20p.

Trellus Health currently has 161,508,333 shares in issue. The market capitalisation of Trellus Health is £2.66 million. Trellus Health has a price to earnings ratio (PE ratio) of -0.42.

Trellus Health Share Discussion Threads

Showing 201 to 225 of 325 messages
Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older
I note the large volume yesterday.
Edit to the above post - In short, it takes time to build up capabilities and develop technology, but it's easier and faster to acquire (or strategically partner with) those who now look attractively affordable. Hence, it's likely we will see M&A activity heat up accordingly going forwards.
I would also add that the market backdrop has resulted in many valuations being significantly reduced, and will mean that affected companies, especially those such as Trellus with 'scientifically validated' methods delivered by technology, are likely to come on to certain radars.

In Trellus's case, there is the potential from companies looking to pivot, or pivot further, into chronic disease management, either via partnering or acquisition.

In short, it takes time to build up capabilities and develop technology, but it's easier and faster to acquire (or strategically partner with) those who now look attractively affordable. Hence, it's likely we will see M&A activity heat up accordingly going forwards.

Cambridgedon...As I allude to in post 211, it looks predominantly like a cash burn reduction exercise and a reflection of who can effectively lead Trellus in the current market, and perhaps more passionately lead and effectively deliver on the strategy, given the new CEO is a co-founder and has unrivalled expertise and reputation in Trellus Health's 'initial' market focus.

We may get further clarification in Interim Results ended June 30th 2022.

Does anyone know/have a theory as to why Monique Fayad went??
The share price has certainly bombed since the announcement.

By my estimates, the shares are currently worth considerably less than the cash element i.e. cash is likely to be currently north of £20m and with a market cap under £15m.

And one assumes, due to the recent announcement, that cash burn, which had already been carefully managed, has been further reduced.

Although I am not sure what the prospects offer given those cut backs and indeed the market backdrop etc.

24p of shares traded market cap dropped by 5% over £800,000 corruption IMHO
Still not showing properly within any of my Barclays accounts.

I escalated this shambolic situation to an official complaint with Barclays 'many months' ago, as it also happened with Verici, which are still not registered in my accounts!

I am pushing for 'definitive' answers on exactly why they have been unable to properly register the shares into my accounts.

Chased it again last week, to include Trellus Health, they are still looking into the matters, implying it was complicated in defining who is at fault and why.

Thanks adobbing.
Mine showed up around the 24th June, in my ii ISA account
A J Bell still not showing my in-specie shares!
Anyone got them showing properly in their portfolios?

Edit - link to correct article added in the above post
We're thrilled to announce the official nationwide launch of Trellus Health for all people age 16+ in the US living with Crohn's disease and Ulcerative Colitis -

Trellus Health appear to be in an area that may be somewhat 'differentiated' from the digital health crowd -

Market downturn dampens digital health funding, M&A in 2022. These sectors raked in the most cash
By Heather Landi
Jul 12, 2022

"Venture investors raised record funds last year, meaning they will have capital to deploy for years to come," the researchers wrote. "Meanwhile, startups are using this market moment to reconsider valuations, trim costs, and, in some cases, people, and refine go-to-market strategies. We foresee these startup adjustments activating savvy M&A deal-makers in H2 2022, with pairings between complementary digital health companies likely leading H2 2022 M&A activity."

Digital mental healthcare also continued to be a hot sector, raising a combined $1.3 billion in the first half of 2022 to again reach the top-funded clinical spot, led by Lyra’s $235 million raise in January. However, of that $1.3 billion just $300 million closed in Q2 2022—possibly signaling a slowdown.

Full story -

The Accidental GastroPsychologist: Building A Business From Behavior Support
07 Jul 2022

Executive Summary
Digital health platforms that offer personalized support are gaining traction in the market, both from patients and investors. Trellus Health is connecting IBD patients with resilience methodologies that enable disease management at lower healthcare costs. Its co-founder Laurie Keefer talks to In Vivo about scaling up the business for greater reach within the market.

You need to sign up for a free trial to get access.

It really is but the market is trading irrationally at the minute. These are in bargain territory
Valued significantly below cash absolute insanity IMHO
Having watched the recent presentation and the fact they forecast profitability q4 next year and won't need to come back to the market.
Currently valued at less than cash the ip and infrastructure is worth a significant amount. Too cheap imho

By the time this dividend lands in my account I doubt it will even buy me a bowl of soup.
Digital Health Center of Excellence Updates from CDRH
U.S. Food and Drug Administration sent this bulletin at 06/27/2022

June 27, 2022

Digital health is driving a revolution in health care, and the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) is helping set the stage for these advances. As an important step in promoting the advancement of digital health technology, CDRH established the Digital Health Center of Excellence (DHCoE). This update highlights DHCoE activities that promote awareness and consistent application of digital health regulatory policies to foster equity in health care; pioneer the development and enhancement of digital health regulatory paradigms; and cultivate digital health-focused collaborations.

Discover how CDRH’s Digital Health Center of Excellence is helping set the stage for the advancement of digital health technologies to help protect and promote public health.

First a quick summary/reminder -

Trellus Health is a leading pioneer in validated resilience-driven care and the first digital health company focused on the intersection of chronic physical conditions and mental health.

Trellus Health's digital-first chronic care management solution integrates convenient access to a licensed multidisciplinary care team with a suite of tools for resilience assessment, education and behavior modification, remote monitoring, health maintenance and prevention. Through its TrellusElevate™ connected care platform and companion App, the Company enables coordination and delivery of expert whole-person care, addressing both clinical and behavioral health together, in context, to improve outcomes and reduce healthcare costs for patients, employers, and the healthcare system.

Thus, I found the following very interesting and encouraging -

Telehealth visits for mental health continue to rise despite dropping in every other specialty
Mental health is bucking the overall trend in telehealth utilization. A new report found that telehealth accounted for 87% of mental health appointments booked last month. That percentage is continuing to climb, despite virtual care visits declining across all other specialties.

Jun 23, 2022

The explosive use of virtual care that occurred during the early months of the pandemic has dropped drastically across all specialties but one — mental health. In fact, telehealth utilization among mental health patients is continuing to climb, according to a new report.

By contrast, when telehealth use for mental health appointments was examined, the numbers tell a different story. In May 2020, 74% of mental health appointments booked on Zocdoc were virtual. It rose to 85% in May 2021 and 87% in May 2022.

Virtual mental health visits will continue to grow, said Richard Fine, Zocdoc’s chief commercial officer. He said that while every other specialty has shifted back to in-person care, mental health is pivoting even more toward telehealth.

“The conversational nature of mental health appointments — and the discretion, ease and efficiency of talking to a therapist from home without a commute — means that telehealth is likely to remain patients’ first choice for mental health care,” he said.

The Report referred to -

@sharw My TRLS in specie shares have now appeared in my ISA account.
I’m now the proud owner of 92 shares worth a grand total of £15.64 😂

Although I had cooled on my personal investment rationale for Trellus Health (I still hold), mainly due the vast amount of competition from the raft of digital health companies, where inevitably there is some overlap with regard to addressing chronic conditions.

Todays news of a recent hire reminded me that Trellus is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management. And that the Trellus approach is based on a scientifically validated method developed at the Mount Sinai Health System.

With the above in mind, the following provides food for thought in terms of Trellus perhaps having an important edge in the digital health sector wallowing in cash, but with not many of those companies being 'differentiated' or indeed scientifically validated -

Lack of clinical evidence ‘major gap’ in digital health: study
Published June 22, 2022

Dive Brief:
Most digital health companies have a low level of “clinical robustness” as measured by their number of regulatory filings and clinical trials, according to a paper published in the Journal of Medical Internet Research.

Researchers at Rock Health and Johns Hopkins University analyzed the activity of 224 companies that have collectively raised $8.2 billion since 2011 to determine their clinical rigor. The median score on the robustness scale was one, reflecting the fact that almost half of the companies had no regulatory filings or clinical trials to their names.

The researchers framed the low clinical robustness scores as evidence of “a major gap in health care technology,” adding that there is a “significant opportunity” for companies that differentiate themselves through a more rigorous approach.
Full article -

The Rock Health Report -

Back in February, Trellus also launched a Program to accelerate patient recruitment and real-world evidence for whole-person resilience driven care management for people living with Inflammatory Bowel Disease (IBD) -

As previously stated in the Company’s trading update from December 2021, the focus for 2022 will be on recruitment of DTC patients and the establishment of additional demonstration programs and B2B contracts. This will enable Trellus to gather real world evidence to validate and reinforce the health quality and economic outcomes shown in the co-founders’ published research, as well as informing further product development.

Recently published clinical research demonstrated that IBD patients show significant improvements in resilience and reductions in expensive unplanned healthcare usage by utilising the GRITTTM methodology and multidisciplinary care model that was exclusively licensed from the Icahn School of Medicine at Mount Sinai. As greater evidence is amassed in 2022, the Company expects to enter regional and national multi-year contracts with US employers and health insurance payers from 2023 onwards.

Got the same email a while after you posted, good to see something finally happening!
AT LAST! No reply from Walbrook but my ii a/c now says:

Event Type
Mandatory Conversion

Please be aware that the restrictions on the Trellus Health A shares issued as in-specie distribution from EKF Diagnostics in December 2020 have now been lifted.

We have now received the new unrestricted Ordinary share certificates in Trellus Health plc and are currently depositing these into electronic format. Once this is complete your account will be updated with the new shares and you will be able to trade the shares through our website as normal.

I am wondering whether EKF failed to make clear at the time what they said yesterday regarding Verici Dx that it is not instant on expiry:

Within 28 days of the expiry of the Lock-up Period, Relevant EKF Shareholders will be sent a certificate for the number of Investment Verici Shares indicated above, which shareholders will then have the option to dematerialise and hold via CREST.

Thanks sharw
Let me know if you hear anything, I’m not desperate for the cash, which is probably not much anyway.
It would be good to resolve, though!

Chat Pages: 13  12  11  10  9  8  7  6  5  4  3  2  Older

Your Recent History

Delayed Upgrade Clock